Arrowhead Pharmaceuticals, Inc. (ARWR) — Financial statements
Income statement, balance sheet, and cash flow for Arrowhead Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 829↑23258.2% | 4↓98.5% | 241↓1.0% | 243↑75.9% | 138 | |
| Cost of Revenue | 0.00↓100.0% | 19↑48.8% | 12↑19.9% | 10 | 0.00 | |
| Gross Profit | 829↑5613.5% | -15↓106.6% | 228↓2.0% | 233 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 607↑24.1% | 489↑42.9% | 342↑18.7% | 289↑45.0% | 199 | |
| General & Administrative Expenses | 122 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 122↑25.9% | 97↑6.5% | 91↓26.0% | 123↑53.4% | 80 | |
| Other Expenses | 2 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 731↑24.8% | 586↑35.3% | 433↑5.3% | 411↑47.4% | 279 | |
| Total Costs & Expenses | 731↑20.9% | 605↑35.6% | 446↑5.7% | 422↑46.8% | 287 | |
| Operating Results | ||||||
| Operating Income | 98↑116.4% | -601↓193.2% | -205↓14.8% | -179↓19.8% | -149 | |
| Depreciation & Amortization | 24↑28.7% | 19↑48.8% | 12↑19.9% | 10↑26.1% | 8 | |
| EBITDA | 165↑129.4% | -562↓219.6% | -176↓8.2% | -162↓22.4% | -133 | |
| EBIT | 141↑124.3% | -580↓208.3% | -188↓8.9% | -173↓22.6% | -141 | |
| Interest & Other Income | ||||||
| Net Interest Income | -52↓440.6% | -10↓218.2% | -3↓160.1% | 5↓17.8% | 6 | |
| Interest Income | 37↑64.1% | 23↑48.5% | 15↑204.0% | 5↓17.8% | 6 | |
| Interest Expense | 89↑176.2% | 32↑76.5% | 18 | 0.00 | 0.00 | |
| Non-Operating Income | -43↓102.9% | -21↓24.6% | -17↓190.4% | -6↑29.2% | -8 | |
| Other Income / Expenses | -47↓311.4% | -11↓664.3% | -1↓125.7% | 6↓29.2% | 8 | |
| Income Before Tax | 52↑108.4% | -612↓196.6% | -206↓19.6% | -173↓22.6% | -141 | |
| Income Tax Expense | 21↑874.1% | -3↓199.4% | 3↓26.4% | 4↑189150.0% | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 30↑104.9% | -610↓191.3% | -209↓18.6% | -176↓25.3% | -141 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -2↑99.7% | -599↓192.0% | -205↓16.6% | -176↓25.0% | -141 | |
| Bottom-Line Net Income | -2↑99.7% | -599↓192.0% | -205↓16.6% | -176↓25.0% | -141 | |
| EPS (Basic) | -0.01↑99.8% | -5.00↓161.8% | -1.91↓14.4% | -1.67↓22.8% | -1.36 | |
| EPS (Diluted) | -0.01↑99.8% | -5.00↓160.4% | -1.92↓15.0% | -1.67↓22.8% | -1.36 | |
| Weighted Average Shares | 134↑11.7% | 120↑11.6% | 107↑1.8% | 105↑1.6% | 104 | |
| Weighted Average Diluted Shares | 134↑11.7% | 120↑12.2% | 107↑1.3% | 105↑1.6% | 104 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.